1. Scrip
  2. >>Business

Sarepta’s $852m Summit Collaboration Could Enable DMD Drug Combinations

 
• By Mandy Jackson

Sarepta committed up to $562m for European and other rights to Summit’s lead DMD drug candidate ezutromid plus additional fees for other utrophin modulators in a deal announced on Oct. 4 that could enable combination therapy regimens.

Sarepta Therapeutics Inc. and Summit Therapeutics PLC entered into an $852m collaboration that could lead to one of the first combination therapy regimens for the treatment of Duchenne muscular dystrophy (DMD) following US FDA approval of Sarepta’s Exondys 51 (eteplirsen), the first medicine ever approved to treat the rare, degenerative, neuromuscular disease.

Cambridge, Massachusetts-based Sarepta paid $40m up front and committed up to $522m in development, regulatory and commercial milestone fees plus...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Finance Watch: MapLight’s Mega-Round Funds Exploration Of Its Cobenfy Competitor

 
• By Mandy Jackson

Private Company Edition: MapLight raised a $372.5m series D round to fund ongoing Phase II trials and investigation of additional indications for its M1/M4 muscarinic agonist. Also, Scrip spoke with Modi Ventures about its new fund.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By Joseph Haas

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

EU 15% Tariff Deal Still Leaves Questions For Pharma

 
• By Jessica Merrill

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By Kevin Grogan

Comes Days After PDUFA Pushback For GSK's Blenrep.

More from Scrip

EU 15% Tariff Deal Still Leaves Questions For Pharma

 
• By Jessica Merrill

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 
• By Andrew McConaghie

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By Kevin Grogan

Comes Days After PDUFA Pushback For GSK's Blenrep.